Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital has shown significant growth from March 2022 to March 2025, with net sales increasing from 400.94 crore to 880.49 crore, and profit after tax rising from 44.16 crore to 130.55 crore, alongside a substantial improvement in total assets and cash flow. Overall, the hospital has demonstrated robust revenue and profitability growth during this period.

Yatharth Hospital has shown significant growth over the past four years, with net sales increasing from INR 400.94 crore to INR 880.49 crore, and profit after tax rising from INR 44.16 crore to INR 130.55 crore, alongside improved financial stability and a reduction in total debt. Total assets surged from INR 420.57 crore to INR 1,713.06 crore, reflecting robust revenue and profitability growth.

As of 07-Nov, Yatharth Hospital & Trauma Care Services Ltd's stock price is Rs 784.95, down 1.26% today and has declined 4.43% over the last two days. Despite this short-term drop, the stock has a positive monthly return of 3.08% and a strong yearly return of 17.69%, supported by solid fundamentals and low debt.

As of November 3, 2025, Yatharth Hospital's technical trend is mildly bullish, supported by a bullish MACD and moving averages, though caution is advised due to a mildly bearish KST and lack of momentum in the RSI.

As of October 8, 2025, Yatharth Hospital is considered very expensive and overvalued, with a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, despite having a lower PE ratio than peers like Max Healthcare and Fortis Healthcare, while significantly outperforming the Sensex with a year-to-date return of 46.93%.

As of 08-Oct, Yatharth Hospital & Trauma Care Services Ltd's stock price has risen to Rs 831.65, marking a 9.21% increase and a new 52-week high of Rs 843. The stock has outperformed the sector significantly, with a 48.22% return over the past year, despite a decline in investor participation.

As of October 7, 2025, Yatharth Hospital is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 51.60 and other valuation metrics, despite outperforming the Sensex over the past year.

As of October 6, 2025, Yatharth Hospital is considered very expensive with a PE Ratio of 52.96, an EV to EBITDA of 30.41, and a Price to Book Value of 4.69, indicating overvaluation despite a strong year-to-date return of 38.08% compared to the Sensex's 4.67%.

As of 06-Oct, Yatharth Hospital & Trauma Care Services Ltd is currently priced at Rs 781.55, reflecting a 4.91% increase. The stock has shown strong performance, trading above key moving averages and significantly outperforming the Sensex over the past year.

As of 30-Sep, Yatharth Hospital & Trauma Care Services Ltd's stock price is at 750.00, reflecting a slight decline of 0.3%. Despite recent short-term challenges, the stock has shown strong monthly and year-to-date returns, outperforming the benchmark Sensex and indicating continued investor interest.

As of September 29, 2025, Yatharth Hospital is considered overvalued with high valuation ratios, including a PE ratio of 50.84, despite outperforming the Sensex year-to-date with a return of 32.56%.